Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16283377 | 0.89 | KDM4E (0.38) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL18216685 | 0.79 | PTGS1 (0.36) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL15033316 | 0.79 | KDM4E (0.33) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16283420 | 0.76 | MMP3 (0.30) | MMP3 | |
| SCHEMBL16283419 | 0.75 | MMP3 (0.45) | MMP3KDM4EMAPTTHRBALOX15 | |
| SCHEMBL22963792 | 0.75 | KDM4E (0.39) | MMP3KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13131308 | 0.75 | KDM4E (0.39) | MMP3KDM4EMAPTTHRBALOX15 | |
| SCHEMBL17708242 | 0.73 | — | — | |
| SCHEMBL15033258 | 0.71 | — | — | |
| SCHEMBL11116277 | 0.70 | BMP1 (0.40) | MMP3KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303247-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | IGENICA BIOTHERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | SDCBP, CD81, DSTN | MMP3 1157/4885KDM4E 2339/4885MAPT 1212/4885 |
| US-20160303247-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | SDCBP, CD81, NGLY1 | MMP3 1107/4885KDM4E 1917/4885MAPT 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.